References
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med [Internet]. 2005 Mar;352(10):987–996.
- Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014;16(January):viii7–viii13.
- Jue TR, McDonald KL. The challenges associated with molecular targeted therapies for glioblastoma. J Neurooncol [Internet]. 2016 May 22:127(3):427–434.
- Malkki H. Trial watch: glioblastoma vaccine therapy disappointment in phase III trial. Nat Rev Neurol [Internet]. 2016 Mar 29:12(4):190–190.
- Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol [Internet]. 2010 Nov;28(31):4722–4729.
- Polivka J, Polivka J, Holubec L, et al. Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme. Anticancer Res [Internet]. 2017 Jan 1:37(1):21–33.
- Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res [Internet]. 2007 Feb 15:13(4):1253–1259.
- Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med [Internet]. 2014;370(8):709–722.
- Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med [Internet]. 2014 Feb 20:370(8):699–708.
- Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell [Internet]. 2010 Jan;17(1):98–110.
- Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell [Internet]. 2011 Dec;20(6):810–817.
- Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell [Internet]. 2006 Mar;9(3):157–173.
- Mehta M, Wen P, Nishikawa R, et al. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol [Internet]. 2017 Mar;111:60–65.
- Stupp R, Taillibert S, Kanner AA et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA [Internet]. 2015 Dec 15;314(23):2535.
- Hefi M, et al. CT007 - Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): final results of a randomized, multi-center, phase III trial. In: Proceedings of the AACR Annual Meeting Abstract CT007 Internet. 2017.
- Wick W. TTFields: where does all the skepticism come from? Neuro Oncol [Internet]. 2016 Mar 25:18(3):303–305.
- Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol [Internet]. 2016 Aug;18(8):1129–1136.
- Schiff D, Schrag D. Living in a material world: tumor-treating fields at the top of the charts. Neuro Oncol [Internet]. 2016 Aug 5:18(8):1033–1034.
- Reardon DA, Wen PY, Wucherpfennig KW, et al. Immunomodulation for glioblastoma. Curr Opin Neurol [Internet]. 2017 Jun;30(3):361–369.
- Srinivasan VM, Ferguson SD, Lee S, et al. Tumor vaccines for malignant gliomas. Neurotherapeutics [Internet]. 2017 Apr 7:14(2):345–357.
- Reardon DA, Omuro A, Brandes AA, et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: checkmate 143. Neuro Oncol [Internet]. 2017 Apr;19(suppl_3):iii21–iii21.
- Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther [Internet]. 2016 Apr 1:15(4):661–669.